

To,

The Manager-Listing

24.07.2023

National Stock Exchange of India Ltd

Mumbai.

**BSE** Limited

Mumbai.

Dear Sir,

Sub: Reporting of Initial Disclosure to be made by entity as Large Corporate.

Pursuant to SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, read with SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/049 dated March 31, 2023, we confirm that Bal Pharma Limited is not a Large Corporate as per the applicability criteria mentioned in Chapter XII - clause 1.2 of the said Operational Circular for the financial year 2023-24. The details required as per Annexure A of the said circular are enclosed.

Please take this intimation on record.

For Bal Pharma Limited

V HIMESH

**Authorized Signatory** 



## Annexure A

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate

SI No	Particulars	Details
01	Name of the Company	Bal Pharma Limited
02	CIN Number	L85110KA1987PLC008368
03	Outstanding borrowing of company	Rs.71.00 Crores
	as on 31st March 2023, as	
	applicable (in Rs cr)	
04	Highest Credit Rating During the	BBB-
	previous FY along with name of the	ACUITE
	Credit Rating Agency	
05	Name of Stock Exchange in which	Not applicable
	the fine shall be paid, in case of	
	shortfall in the required borrowing	
	under the framework.	

We confirm that <u>we are not a Large Corporate</u> as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.

For Bal Pharma Limited

Daylari growth by HAMES1
Dock - Rh parladors and the HAMES1
See - Rh parladors - Rh parlado

**Authorized Signatory** 

CORPORATE OFFICE: 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India
Ph.: 91 - 80 - 41379500 Fax: 91 - 80 - 22354057 / 58

Email: info@balpharma.com Website: www.balpharma.com

CIN # L85110KA1987PLC008368